Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Abacavir · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Abacavir sulfate | DRUG | - |
| Amprenavir | DRUG | - |
| Efavirenz | DRUG | - |
| Adefovir dipivoxil | DRUG | - |
Inclusion Criteria You may be eligible for this study if you: * Are HIV-positive. * Had an HIV level of at least 2,000 copies/ml after 6 months of treatment with at least 1 PI other than amprenavir (meaning you failed PI treatment). * Are at least 13 years old (need consent of parent or guardian i...
Top 20 of 28 competitors
Abacavir is a small molecule drug being developed by Gilead Sciences, Inc. for the treatment of HIV Infections. It is currently in Phase 2 clinical development as an investigational therapy. The drug has been studied in a completed clinical trial involving 25 patients with HIV Infections.
Abacavir is being developed by Gilead Sciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol GILD. The company is conducting clinical research on this small molecule drug for the treatment of HIV Infections.
Abacavir is currently in Phase 2 clinical development. It is an investigational drug for the treatment of HIV Infections and has not been approved by regulatory authorities. One Phase 2 clinical trial for Abacavir has been completed.
Abacavir has one completed clinical trial registered under NCT00002419. This Phase 2 study evaluated the safety and effectiveness of giving Adefovir Dipivoxil plus Abacavir plus Efavirenz plus Amprenavir to HIV-infected patients who had failed to respond to previous protease inhibitor treatment. The trial enrolled 25 participants in the United States.
Abacavir is the primary name for this drug candidate developed by Gilead Sciences, Inc. No alternative names for Abacavir have been identified in the available clinical trial information. The drug is being studied under its current name in clinical research.